Literature DB >> 19814658

Synthetic vehicles for DNA vaccination.

Joost H van den Berg1, Bastiaan Nuijen, Ton N Schumacher, John B A G Haanen, Gert Storm, Jos H Beijnen, Wim E Hennink.   

Abstract

DNA vaccination is an attractive immunization method able to induce robust cellular immune responses in pre-clinical models. However, clinical DNA vaccination trials performed thus far have resulted in marginal responses. Consequently, strategies are currently under development to improve the efficacy of DNA vaccines. A promising strategy is the use of synthetic particle formulations as carrier systems for DNA vaccines. This review discusses commonly used synthetic carriers for DNA vaccination and provides an overview of in vivo studies that use this strategy. Future recommendations on particle characteristics, target cell types and evaluation models are suggested for the potential improvement of current and novel particle delivery systems. Finally, hurdles which need to be tackled for clinical evaluation of these systems are discussed.

Mesh:

Substances:

Year:  2010        PMID: 19814658     DOI: 10.3109/10611860903278023

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  4 in total

1.  Transgene expression and local tissue distribution of naked and polymer-condensed plasmid DNA after intradermal administration in mice.

Authors:  R Noelle Palumbo; Xiao Zhong; David Panus; Wenqing Han; Weihang Ji; Chun Wang
Journal:  J Control Release       Date:  2012-01-24       Impact factor: 9.776

2.  Stimulator of interferon genes agonists attenuate type I diabetes progression in NOD mice.

Authors:  Henrique Lemos; Eslam Mohamed; Lei Huang; Phillip R Chandler; Rong Ou; Rafal Pacholczyk; Andrew L Mellor
Journal:  Immunology       Date:  2019-10-15       Impact factor: 7.397

3.  Impact of the Charge Ratio on the In Vivo Immunogenicity of Lipoplexes.

Authors:  Zahra Heidari; Jaspreet S Arora; Dibyadyuti Datta; Vijay T John; Nirbhay Kumar; Geetha P Bansal
Journal:  Pharm Res       Date:  2017-05-30       Impact factor: 4.200

4.  Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma.

Authors:  A N Meleshko; N A Petrovskaya; N Savelyeva; K P Vashkevich; S N Doronina; N V Sachivko
Journal:  Hum Vaccin Immunother       Date:  2017-03-08       Impact factor: 3.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.